A p38 MAPK-MEF2C pathway regulates B-cell proliferation.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 18955699.
- Also identified by DOI 10.1073/pnas.0804868105 and PMC identifier 2579379.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
B lymphocytes are an integral part of the adaptive immune system. On antigen binding to the B-cell receptor (BCR), B cells rapidly proliferate and differentiate into antibody-secreting plasma cells. The p38 mitogen-activated protein kinase (MAPK) pathway functions downstream of the BCR to control cell proliferation, but the transcriptional effectors of this pathway in B cells have remained elusive. In the present study, we inactivated Mef2c exclusively in B cells by conditional gene targeting in mice. Loss of MEF2C function resulted in a reduced immune response to antigen, defective germinal center formation, and a severe defect in B-cell proliferation, and we show that MEF2C regulates proliferation in response to BCR stimulation via the p38 MAPK pathway. p38 directly phosphorylates MEF2C via three residues in the C-terminal transactivation domain, establishing MEF2C as a direct transcriptional effector of BCR signaling via p38 MAPK.
Medical subject headings
- B-Lymphocytes
- MAP Kinase Signaling System
- Myogenic Regulatory Factors
- p38 Mitogen-Activated Protein Kinases